Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.
Diabetes Metab J. 2011 Jun;35(3):236-42. doi: 10.4093/dmj.2011.35.3.236. Epub 2011 Jun 30.
Hypertension and type 2 diabetes mellitus are major risk factors for cardiovascular disease. This study analyzed the changes in central aortic waveforms and pulse wave velocity as well as related parameters after treatment with valsartan, an angiotensin II type 1 receptor blocker, in patients with type 2 diabetes and hypertension.
We used pulse wave analysis to measure central aortic waveform in a total of 98 subjects. In 47 of these patients, pulse wave velocity measurements were obtained before and after 12 weeks of treatment with valsartan.
In the central aortic waveform analysis, the aortic pulse pressure and augmentation index were significantly decreased after valsartan treatment, as was the aortic pulse wave velocity. Factors contributing to the improvement in pulse wave velocity were the fasting blood glucose and haemoglobin A1c levels.
Short-term treatment with valsartan improves arterial stiffness in patients with type 2 diabetes and hypertension, and the glucose status at baseline was associated with this effect.
高血压和 2 型糖尿病是心血管疾病的主要危险因素。本研究分析了血管紧张素 II 型 1 型受体阻滞剂缬沙坦治疗 2 型糖尿病合并高血压患者后中心主动脉波形和脉搏波速度及相关参数的变化。
我们使用脉搏波分析测量了 98 例患者的中心主动脉波形。其中 47 例患者在接受缬沙坦治疗 12 周前后进行了脉搏波速度测量。
在中心主动脉波形分析中，主动脉脉搏压和增强指数在缬沙坦治疗后明显降低，主动脉脉搏波速度也降低。与脉搏波速度改善相关的因素是空腹血糖和糖化血红蛋白水平。
短期使用缬沙坦可改善 2 型糖尿病合并高血压患者的动脉僵硬度，且基线时的血糖状况与该效应相关。
